Calypte Biomedical Corporation (CYPT) and Maxim Biomedical Announce Joint Distribution of Incidence Testing Assays
4/25/2013 1:25:29 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PORTLAND, Ore., April 25, 2013 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (OTCBB:CBMC) and Maxim Biomedical Inc. today announced a reciprocal distribution agreement under which customers may purchase from either company, on the same terms, both Calypte's Aware™ BED EIA HIV-1 Incidence Test and Maxim's HIV-1 Limiting Antigen (LAg)-Avidity EIA Kit.
Help employers find you! Check out all the jobs and post your resume.
comments powered by